
Robert H. Getzenberg
Advertisement
Articles by Robert H. Getzenberg


Advertisement
Latest Updated Articles
7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 InhibitorPublished: April 18th 2022 | Updated:
8 TiP Randomized, Multicenter, Phase 3 Study to Evaluate the Combination of Enobosarm and Abemaciclib Compared With Estrogen-Blocking Agent for the Second-Line Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Have Previously Received Palbociclib and an Estrogen-Blocking Agent Combination TherapyPublished: April 18th 2022 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Spotlighting the Top 10 FDA Oncology Approvals in 2025
2
Ivosidenib Combo Shows Preliminary Activity in IDH1-Mutated AML
3
What’s New in Hematology/Oncology? Discussing the 2025 ASH Annual Meeting
4
Nab-Sirolimus Regimens Show Promise in HR+/HER2-Negative Breast Cancer
5

